Jazz Pharmaceuticals (JAZZ) Misses Q1 EPS by 11c
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $246.81 -0.31%
EPS Growth %: -20.5%
Financial Fact:
Total revenues: 374.18M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -20.5%
Financial Fact:
Total revenues: 374.18M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q1 EPS of $3.73, $0.11 worse than the analyst estimate of $3.84. Revenue for the quarter came in at $813.7 million versus the consensus estimate of $852.75 million.
GUIDANCE:
Jazz Pharmaceuticals raises FY2022 revenue to $3.5-3.7 billion, versus the consensus of $3.58 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Asana, Inc. (ASAN) Tops Q2 EPS by 1c; offers guidance
- Torrid Holdings Inc. (CURV) Tops Q2 EPS by 8c; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
